JP2003520835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520835A5 JP2003520835A5 JP2001555021A JP2001555021A JP2003520835A5 JP 2003520835 A5 JP2003520835 A5 JP 2003520835A5 JP 2001555021 A JP2001555021 A JP 2001555021A JP 2001555021 A JP2001555021 A JP 2001555021A JP 2003520835 A5 JP2003520835 A5 JP 2003520835A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- hexyloxy
- carboxy
- dimethylhexanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 42
- 239000013078 crystal Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012265 solid product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- -1 (Carboxy-5-methyl-hexyloxy) -2,2-dimethylhexanoic acid monocalcium salt Chemical compound 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- CGKGNTKAFQPCEF-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate;hydrate Chemical compound O.[Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O CGKGNTKAFQPCEF-UHFFFAOYSA-L 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- PXJJTOXDLJBGSN-UHFFFAOYSA-L calcium 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound CC(C)(CCCCOCCCCC(C)(C)C(=O)[O-])C(=O)O.CC(C)(CCCCOCCCCC(C)(C)C(=O)[O-])C(=O)O.[Ca+2] PXJJTOXDLJBGSN-UHFFFAOYSA-L 0.000 description 2
- ZQNPDAVSHFGLIQ-UHFFFAOYSA-N calcium;hydrate Chemical compound O.[Ca] ZQNPDAVSHFGLIQ-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- KQLOVQYKZKXANH-UHFFFAOYSA-N CCC[Ca] Chemical class CCC[Ca] KQLOVQYKZKXANH-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- LUUSKZKEUDPIHB-UHFFFAOYSA-L calcium 2,2-dimethylhexanoate hydrate Chemical group O.[Ca++].CCCCC(C)(C)C([O-])=O.CCCCC(C)(C)C([O-])=O LUUSKZKEUDPIHB-UHFFFAOYSA-L 0.000 description 1
- HYRHCZQDONUBBM-UHFFFAOYSA-L calcium 6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate methanol Chemical compound [Ca++].CO.CC(C)(CCCCOCCCCC(C)(C)C([O-])=O)C([O-])=O HYRHCZQDONUBBM-UHFFFAOYSA-L 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- ZSXJMJATFFOPJZ-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate;ethanol Chemical compound [Ca+2].CCO.[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZSXJMJATFFOPJZ-UHFFFAOYSA-L 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17782300P | 2000-01-25 | 2000-01-25 | |
| US60/177,823 | 2000-01-25 | ||
| PCT/IB2001/000026 WO2001055078A1 (en) | 2000-01-25 | 2001-01-11 | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520835A JP2003520835A (ja) | 2003-07-08 |
| JP2003520835A5 true JP2003520835A5 (OSRAM) | 2006-01-12 |
| JP4750995B2 JP4750995B2 (ja) | 2011-08-17 |
Family
ID=22650106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001555021A Expired - Fee Related JP4750995B2 (ja) | 2000-01-25 | 2001-01-11 | カルシウムジカルボキシレートエーテル、その製造法、及びそれを用いた血管系疾患及び糖尿病の治療 |
Country Status (39)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1045691T1 (en) * | 1997-12-12 | 2005-04-30 | Warner-Lambert Company Llc | Statin-carboxyalkylether combinations |
| AU2003255937A1 (en) * | 2002-08-22 | 2004-03-11 | Warner-Lambert Company Llc | Method of treating osteoarthritis |
| US7816405B2 (en) | 2005-04-19 | 2010-10-19 | Eisai R&D Management Co., Ltd. | Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof |
| EP1873141A4 (en) * | 2005-04-19 | 2010-09-22 | Eisai R&D Man Co Ltd | CALCIUM-BIS [2S] -3- [3- (2S) -3- (4-CHLORO-2-CYANOPHENOXY) -2-FLUORO-PROPOXYPHENYL] -2-ISOPROPOXYPROPIONATE] AND INTERMEDIATE PRODUCTS THEREOF |
| CN107108442A (zh) * | 2014-11-14 | 2017-08-29 | 燿石治疗公司 | 用于制备α,ω‑二羧酸封端的二烷醚的方法和中间体 |
| IL269884B2 (en) * | 2017-04-18 | 2023-09-01 | Gemphire Therapeutics Inc | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use |
| EP3867222A4 (en) * | 2018-10-18 | 2022-07-06 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
-
2001
- 2001-01-11 SK SK1062-2002A patent/SK10622002A3/sk not_active Application Discontinuation
- 2001-01-11 HU HU0204422A patent/HUP0204422A3/hu unknown
- 2001-01-11 JP JP2001555021A patent/JP4750995B2/ja not_active Expired - Fee Related
- 2001-01-11 PL PL01357076A patent/PL357076A1/xx not_active Application Discontinuation
- 2001-01-11 IL IL15054101A patent/IL150541A0/xx unknown
- 2001-01-11 AP APAP/P/2002/002587A patent/AP2002002587A0/en unknown
- 2001-01-11 CN CN01804045A patent/CN1395555A/zh active Pending
- 2001-01-11 GE GE4872A patent/GEP20053428B/en unknown
- 2001-01-11 AU AU22140/01A patent/AU2214001A/en not_active Abandoned
- 2001-01-11 CA CA002397960A patent/CA2397960C/en not_active Expired - Lifetime
- 2001-01-11 AT AT01900037T patent/ATE431326T1/de not_active IP Right Cessation
- 2001-01-11 EE EEP200200404A patent/EE200200404A/xx unknown
- 2001-01-11 NZ NZ519550A patent/NZ519550A/en unknown
- 2001-01-11 BR BR0107763-5A patent/BR0107763A/pt not_active IP Right Cessation
- 2001-01-11 KR KR1020027009519A patent/KR20020073182A/ko not_active Ceased
- 2001-01-11 DZ DZ013239A patent/DZ3239A1/fr active
- 2001-01-11 EP EP01900037A patent/EP1259474B1/en not_active Expired - Lifetime
- 2001-01-11 DK DK01900037T patent/DK1259474T3/da active
- 2001-01-11 MX MXPA02007223A patent/MXPA02007223A/es active IP Right Grant
- 2001-01-11 OA OA1200200226A patent/OA12166A/en unknown
- 2001-01-11 EA EA200200641A patent/EA004862B1/ru not_active IP Right Cessation
- 2001-01-11 CZ CZ20022474A patent/CZ20022474A3/cs unknown
- 2001-01-11 DE DE60138686T patent/DE60138686D1/de not_active Expired - Lifetime
- 2001-01-11 WO PCT/IB2001/000026 patent/WO2001055078A1/en not_active Ceased
- 2001-01-11 ES ES01900037T patent/ES2324281T3/es not_active Expired - Lifetime
- 2001-01-22 UY UY26550A patent/UY26550A1/es not_active Application Discontinuation
- 2001-01-22 SV SV2001000290A patent/SV2002000290A/es not_active Application Discontinuation
- 2001-01-23 AR ARP010100284A patent/AR029436A1/es unknown
- 2001-01-23 GT GT200100015A patent/GT200100015A/es unknown
- 2001-01-23 PA PA20018510601A patent/PA8510601A1/es unknown
- 2001-01-24 TN TNTNSN01013A patent/TNSN01013A1/fr unknown
- 2001-01-24 CO CO01005267A patent/CO5261537A1/es not_active Application Discontinuation
- 2001-01-24 PE PE2001000076A patent/PE20011064A1/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000011A patent/HN2001000011A/es unknown
-
2002
- 2002-06-20 BG BG106851A patent/BG106851A/xx unknown
- 2002-06-25 IS IS6442A patent/IS6442A/is unknown
- 2002-07-22 MA MA26735A patent/MA26867A1/fr unknown
- 2002-07-23 ZA ZA200205880A patent/ZA200205880B/xx unknown
- 2002-07-24 NO NO20023526A patent/NO20023526L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2516471C (en) | Ferric organic compounds, uses thereof and methods of making same | |
| RU2002135589A (ru) | Новая кристаллическая и аморфная форма триазоло(4,5-d) пиримидина | |
| CA2408596A1 (en) | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound | |
| EA019058B1 (ru) | Способ получения кристаллических форм а и в илапразола и способ превращения указанных кристаллических форм | |
| AU2010212923A1 (en) | Novel salts of sitagliptin | |
| KR20170033684A (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
| JP2009527509A5 (OSRAM) | ||
| US10155007B2 (en) | Synthesis method for improved tenofovir disoproxil fumarate using ion-exchange resin and method for preparing oral dissolving film form using the same | |
| CN120641417A (zh) | 齐帕勒替尼的固态形式及其制备方法 | |
| JP2003520835A5 (OSRAM) | ||
| CN101481363B (zh) | 一种制备瑞格列奈的方法 | |
| TWI835325B (zh) | (s)-4-氯-2-胺基丁酸鹽酸鹽及(s)-4-氯-2-胺基丁酸酯的製備方法 | |
| RU2005109560A (ru) | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина | |
| CN103664606A (zh) | 一种氟比洛芬酯类化合物的制备方法 | |
| RU2005105688A (ru) | Полиморфизм додекагидроциклопента (а) фенантренилового эфира тиофенкарбоновой кислоты | |
| KR20090005513A (ko) | 메트포르민 말론산염, 그의 제조 방법 및 그를 포함하는약제학적 조성물 | |
| CN1291978C (zh) | 5－羟基－1－甲基乙内酰脲的新型晶型 | |
| KR101322116B1 (ko) | 치환 페닐알칸산의 신규 결정 및 제조 방법 | |
| JPH10502050A (ja) | 骨関節疾患の治療に有用なｎ−〔｛４，５−ジヒドロキシ−及び４，５，８−トリヒドロキシ−９，１０−ジヒドロ−９，１０−ジオキソ−２−アントラセン−イル｝カルボニル〕アミノ酸 | |
| EA004862B1 (ru) | Кальцийдикарбоксилатные эфиры, способы их получения, фармацевтические композиции и способ лечения | |
| WO2019037591A1 (zh) | 盐酸美法仑晶型及其制备方法与应用 | |
| KR101805684B1 (ko) | 테노포비르 디소프록실 푸마레이트를 이용한 구강용해 필름(odf)제형 및 이의 제조방법 | |
| CN109096133B (zh) | 3-氨基-4-(2,4,5-三氟苯基)丁酸薄荷酯盐酸盐及其制备方法和应用 | |
| KR101513561B1 (ko) | 펙소페나딘 염산염의 신규 제조방법 | |
| BG65567B1 (bg) | Метод за получаване на 6-(4-хлорофенил)-2,2- диметил-7-фенил-2,3-дихидро-1н-пиролизин-5-илoцетна киселина |